My pessimistic take for CC tomorrow is a lot of talk about Baylor study. Pep talk about more enrollees in S/C trial. Discussion of safety review board and finally a projected short turn around date for efficacy analysis, like next Tuesday. My optimistic take is the first three and finally a smiling Nader says we have the analysis completed and the efficacy is excellent. We are submitting to FDA with a request for approval for unmet need.
News 
Market Data 
Discover 
